Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer K Brachmann

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Pharmaceutical Research|June 19, 2012
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humansYan Xin, Shuang Bai, Lisa A Damico-Beyer, et al.
Cancer Research|March 17, 2006
Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylationTakahiko Kobayashi, Ting Wang, Masaji Maezawa, et al.
Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics|October 20, 2006
Functional census of mutation sequence spaces: the example of p53 cancer rescue mutantsSamuel A Danziger, S Joshua Swamidass, Jue Zeng, et al.
International Journal of Cancer|March 24, 2010
p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5Takahiko Kobayashi, Junich Ishida, Manabu Musashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic CancerEfrat Dotan, Dana B Cardin, Heinz-Josef Lenz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical modelsJill M Spoerke, Carol O'Brien, Ling Huw, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumorsAmita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Pharmaceutical Research|June 19, 2012
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humansYan Xin, Shuang Bai, Lisa A Damico-Beyer, et al.
Cancer Research|March 17, 2006
Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylationTakahiko Kobayashi, Ting Wang, Masaji Maezawa, et al.
Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics|October 20, 2006
Functional census of mutation sequence spaces: the example of p53 cancer rescue mutantsSamuel A Danziger, S Joshua Swamidass, Jue Zeng, et al.
International Journal of Cancer|March 24, 2010
p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5Takahiko Kobayashi, Junich Ishida, Manabu Musashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic CancerEfrat Dotan, Dana B Cardin, Heinz-Josef Lenz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical modelsJill M Spoerke, Carol O'Brien, Ling Huw, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumorsAmita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Pageof 2